Publications
| Year | Title | Journal | Authors (First, Last) | PMID |
|---|---|---|---|---|
| 2025 | Cryptococcosis, tuberculosis, and a kidney cancer fail to fit the atherosclerosis paradigm for foam cell lipid content. | bioRxiv [Preprint] | Guerrini V, Gennaro M | 37333211 |
| 2025 | Efficacy of ATR kinase inhibitor elimusertib monotherapy or combination in tumors with DNA damage response pathway and other genomic alterations. | Mol Cancer Ther. | Varadarajan K, Meric-Bernstam F | 40300249 |
| 2025 | Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE. | Front Immunol. | Lyu M, ParMar | 39975551 |
| 2025 | Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer. | Clin Cancer Res. | DiPeri T, Meric-Bernstam F | 39513959 |
| 2024 | CD28 costimulation augments CAR signaling in NK cells via the LCK/CD3ζ/ZAP70 signaling axis. | Cancer Discov. | Acharya S, Rezvani K | 38900051 |
| 2024 | Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes. | Cancer Cell | Heeke S, Heymach J | 38278149 |
| 2023 | Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. | Nat Med | Cascone T, Sepesi B | 36928818 |
| 2023 | Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma. | Nat Commun | Karam JA, Wood CG | 37164948 |
| 2023 | Allogeneic cord blood regulatory T cells decrease dsDNA antibody and improve albuminuria in systemic lupus erythematosus. | Front Immunol | Lyu MA, Parmar S | 37736101 |
| 2023 | Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma. | Clinical Cancer Research | Osman AA, Myers JN | 36689560 |
| 2023 | Immune cellular patterns of distribution affect outcomes of patients with non-small cell lung cancer. | Nat Commun | Parra ER, Wistuba II | 37185575 |
| 2023 | HER2-low expression in patients with advanced or metastatic solid tumors. | Ann Oncol. | Uzunparmak B, Dumbrava EE | 37619847 |
| 2023 | CRISPR–Cas9-based functional interrogation of unconventional translatome reveals human cancer dependency on cryptic non-canonical open reading frames. | Nat Struct Mol Biol | Zheng C, Chen, Y | 37932451 |
See more publications that use the TBPR
Note that this only lists MD Anderson publications from the last five years
Please remember to acknowledge the core in publications that use core services. Go to the acknowledgment page for more information.
Give Now
Your gift will help make a tremendous difference.
Research Areas
Find out about the four types of research taking place at MD Anderson.
Subscribe
Get the latest information on our cancer breakthroughs.